Literature DB >> 32143691

Protein A/G-based enzyme-linked immunosorbent assay for detection of anti-Pythium insidiosum antibodies in human and animal subjects.

Chalisa Jaturapaktrarak1,2, Penpan Payattikul1, Tassanee Lohnoo1, Yothin Kumsang1, Aree Laikul3, Watcharapol Pathomsakulwong4, Chompoonek Yurayart5, Walaiporn Tonpitak6, Theerapong Krajaejun7.   

Abstract

OBJECTIVES: Pythiosis is a deadly infectious disease caused by Pythium insidiosum. Reports of both human and animal pythiosis are on the rise worldwide. Prognosis of the pythiosis patients relies on early diagnosis and prompt treatment. There are needs for an immunodiagnostic test that can detect the disease in both humans and animals. This study aims at reporting an optimized protocol for the development of a protein A/G-based enzyme-linked immunosorbent assay (ELISA) for the detection of anti-P. insidiosum antibody in multiple host species.
RESULTS: A total of 25 pythiosis and 50 control sera, obtained from humans, horses, dogs, cats, and cows, were recruited for the assay development. With a proper ELISA cutoff point, all pythiosis sera can ultimately be distinguished from the control sera. The successfully-developed protein A/G-based ELISA can detect the anti-P. insidiosum antibodies in serum samples of both humans and animals. It is a versatile, feasible-to-develop, and functional immunodiagnostic assay for pythiosis.

Entities:  

Keywords:  ELISA; Immunodiagnosis; Protein A/G; Pythiosis; Pythium insidiosum

Mesh:

Substances:

Year:  2020        PMID: 32143691      PMCID: PMC7059324          DOI: 10.1186/s13104-020-04981-y

Source DB:  PubMed          Journal:  BMC Res Notes        ISSN: 1756-0500


Introduction

Pythiosis is a deadly infectious disease caused by the pathogenic oomycete Pythium insidiosum [1, 2]. The disease affects humans and animals, especially horses and dogs. Geographic distribution of pythiosis covers the tropical and subtropical countries [2]. Pythiosis demonstrates high rates of morbidity and mortality [3]. Most of the affected individuals lose an infected organ, and many patients die from the disease. Prognosis of the pythiosis patients relies on early diagnosis and prompt treatment. Establishing the definitive diagnosis requires a reliable diagnostic method, i.e., organism isolation and identification, immunodiagnostic test, molecular assay, and proteomic analysis [1, 2, 4–13]. Immunodiagnostic tests for pythiosis have gained popularity due to simplicity and short turnaround time. Various immunodiagnostic methods, such as immunodiffusion (ID), enzyme-linked immunosorbent assay (ELISA), hemagglutination (HA), immunochromatographic test (ICT), have been developed to facilitate the diagnosis of pythiosis [10-20]. Each immunodiagnostic test has some advantages/disadvantages over the others. For example, ID and HA detect the antibodies in both humans and animals but possess limited sensitivity. ELISA is a multi-step assay but exhibits relatively-high diagnostic performance. ICT is a rapid and user-friendly assay, but the development of this test is complicated. Because reports of both human and animal pythiosis are on the rise worldwide, there are needs for an immunodiagnostic test that can detect the disease in a broad range of host species. Due to the lack of a versatile, feasible-to-develop, and functional immunodiagnostic assay, the current study aims at reporting an optimized protocol to develop an ELISA for the detection of anti-P. insidiosum antibodies in humans and other animals. The assay relied on the use of protein A/G, which is a molecule that can bind the immunoglobulins from various animal species [16].

Main text

We extracted proteins from the P. insidiosum strain Pi-S [21, 22], using the established method [17, 23]. In short, the organism was maintained on Sabouraud dextrose agar [10 mg/ml peptone (Becton, Dickinson and Company, Maryland, USA), 20 mg/ml dextose (HiMedia Laboratories, Mumbai, India) and 15 mg/ml agar (Becton, Dickinson and Company, Maryland, USA)]. Ten excised agar cubes (~ 0.5 cm3) with P. insidiosum colony were incubated with shaking (150 rpm) at 37 °C for 10 days in 100 ml of Sabouraud dextrose broth. The growing organism was removed from the cultured broth by consecutive filtrations through a filter paper (Whatman No.1, GE healthcare, Belfast, UK) and a 0.22-μm-pore-size Durapore membrane (Merck Millipore, Cork, Ireland). The filtrated broth was concentrated by centrifugation (10,000×g) with an Amicon Ultra 15 M tube (Merck Millipore, Cork, Ireland). The concentrated broth, now called culture filtrate antigen (CFA), was stored at − 30 °C. We developed a multiple host-specific ELISA by modifying the human-specific ELISA protocols of Chareonsirisuthigul et al. [15] and Lohnoo et al. [23]. In brief, a 96-well flat-bottom polystyrene plate (Corning, New York, USA) was coated overnight at 4 °C with 100 µl/well of CFA (5 µg/ml) in 0.1 M carbonate buffer pH 9.6 [0.2 M Na2CO3 and 0.2 M NaHCO3 (Merck, Darmstadt, Germany)] and 1.5% NaCl (Merck, Darmstadt, Germany). The plate was washed 4 times with the washing buffer [phosphate-buffered saline pH 7.4 (PBS); 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 1.76 mM KH2PO (Merck, Darmstadt, Germany) with 0.05% Tween-20 (Calbiochem, California, USA)], blocked with 250 µl of 0.5% bovine serum albumin (Merck, Darmstadt, Germany) in PBS at 37 °C for 60 min, and washed 4 times again. Each serum (1 µl) was added to 9 ul of PBS. Then, the diluted serum (5 µl) was mixed with 795 µl of PBS. The resulting serum sample (1:1600 in PBS; 100 µl) was added to each well and incubated at 37 °C for 60 min. After washing (as above), 100 µl of protein A/G conjugated with peroxidase (Bio-Rad Laboratories, California, USA) (1:100,000 in PBS) was added to each well and stored at 37 °C for 60 min. The ELISA plate was washed once again. Chromogenic substrate [3,3′,5,5′-Tetramethylbenzidine and H2O2 (Thermo Scientific, Rockford, USA)] was applied to each well (100 µl/well) and incubated at room temperature for 3 min in a dark chamber. Sulfuric acid (0.5 N; 100 µl/well) was used to stop the enzymatic reaction. Optical density (OD) of each serum sample was measured at the 450-nm wavelength. A total of 25 serum samples were derived from 20 Thai patients, 4 horses, and a dog with the clinical features of pythiosis [1-3], together with either successful detection of P. insidiosum by culture and molecular analysis [6, 24–26] or serum anti-P. insidiosum antibodies by ICT [16]. Fifty control (negative) sera were obtained from 10 each of individuals, horses, dogs, cats, and cows with no clinical sign of pythiosis in the absence of serum anti-P. insidiosum antibodies by ICT. Positive (from a known pythiosis patient) and negative (from a healthy blood donor) control sera were analyzed in parallel. All serum samples were leftover specimens obtained from the Faculty of Medicine, Ramathibodi Hospital, Mahidol University, and the Faculty of Veterinary Medicine, Kasetsart University. Each serum sample was tested in duplicate by the protein A/G-based ELISA. ELISA value (EV) was an OD value of a serum sample divided by an OD value of the negative control serum. ELISA cutoff value was derived from the mean EV of the control sera plus 2, 3, 4, or 5 standard deviations (SD). Diagnostic performance (i.e., specificity, sensitivity, and accuracy) were calculated as described previously [15] (Table 1). Distribution of EVs (representing a detectable level of anti-P. insidiosum antibodies) of the pythiosis (n = 25) and control (n = 50) sera from both humans and animals was shown in Fig. 1a. Mean EV of the pythiosis sera was 41.0 (range 23.1–46.9), whereas that of the control sera was 3.0 (range 0.4–12.2). The “mean EV + 5SDs” cutoff point (EV, 13.4) provided the best sensitivity, specificity, and accuracy for the detection of the anti-P. insidiosum antibodies (Table 1). Furthermore, protein A/G-based ELISA was performed using serial twofold dilutions (from 1:1600 to 1:102,400) of a serum sample from a human, a horse, and a dog with pythiosis, and a healthy individual (control). The serum dilutions and the obtained EVs of each animal species showed some degree of a linear relationship (i.e., the higher dilution, the lower EV) (Fig. 2). The result suggests that the protein A/G-based ELISA can quantitate an anti-P. insidiosum antibody level for monitoring the clinical course of pythiosis.
Table 1

Correlation between the cutoff points and the diagnostic performance (i.e., sensitivity, specificity, and accuracy) of the protein A/G-based and anti-human IgG antibody-based ELISAs for detection of the anti-P. insidiosum antibodies in serum samples

Cutoff pointaProtein A/G-based ELISAAnti-human IgG antibody-based ELISA
Cutoff value (EV)bSensitivitycSpecificitydAccuracyeCutoff value (EV)SensitivitySpecificityAccuracy
Mean EV + 5SDs13.4f100.0100.0100.018.680.0100.093.3
Mean EV + 4SDs11.3100.098.098.715.4g84.0100.094.7
Mean EV + 3SDs9.3100.098.098.712.284.0100.094.7
Mean EV + 2SDs7.2100.096.097.39.084.098.093.3

aCutoff point = mean EV of the control sera plus 2, 3, 4 or 5 SDs

bELISA value (EV) = OD value of a serum sample/OD value of the negative control serum

cSensitivity (%) = true positive samples/(true positive + false negative samples) × 100

dSpecificity (%) = true negative samples/(true negative + false positive samples) × 100

eAccuracy (%) = (true positive + true negative samples)/all samples × 100

fOptimal cutoff point of the protein A/G-based ELISA

gOptimal cutoff point of the anti-human IgG antibody-based ELISA

Fig. 1

Dot plot of the ELISA values (EV) of pythiosis (n = 25) and control (n = 50) serum samples examined by a the protein A/G-based and b the anti-human IgG antibody-based ELISAs. Different colors indicate the EVs of sera from different animal species. Dashed lines represent the optimal ELISA cutoff points (see Table 1)

Fig. 2

ELISA values (Y-axis) of serial twofold dilutions (from 1:1600 to 1:102,400; X-axis) of a serum sample from a human (blue), a horse (orange), and a dog (gray) with pythiosis, and a healthy individual (served as a control; yellow). The working serum dilution for protein A/G-based ELISA testing is 1:1600 (see text for details)

Correlation between the cutoff points and the diagnostic performance (i.e., sensitivity, specificity, and accuracy) of the protein A/G-based and anti-human IgG antibody-based ELISAs for detection of the anti-P. insidiosum antibodies in serum samples aCutoff point = mean EV of the control sera plus 2, 3, 4 or 5 SDs bELISA value (EV) = OD value of a serum sample/OD value of the negative control serum cSensitivity (%) = true positive samples/(true positive + false negative samples) × 100 dSpecificity (%) = true negative samples/(true negative + false positive samples) × 100 eAccuracy (%) = (true positive + true negative samples)/all samples × 100 fOptimal cutoff point of the protein A/G-based ELISA gOptimal cutoff point of the anti-human IgG antibody-based ELISA Dot plot of the ELISA values (EV) of pythiosis (n = 25) and control (n = 50) serum samples examined by a the protein A/G-based and b the anti-human IgG antibody-based ELISAs. Different colors indicate the EVs of sera from different animal species. Dashed lines represent the optimal ELISA cutoff points (see Table 1) ELISA values (Y-axis) of serial twofold dilutions (from 1:1600 to 1:102,400; X-axis) of a serum sample from a human (blue), a horse (orange), and a dog (gray) with pythiosis, and a healthy individual (served as a control; yellow). The working serum dilution for protein A/G-based ELISA testing is 1:1600 (see text for details) All serum samples were also tested in duplicate by the established human-specific ELISA employing goat anti-human IgG antibody conjugated with peroxidase (Bio-Rad Laboratories, California, USA) [15, 23]. The anti-human IgG antibody-based ELISA with an optimal cutoff point (mean EV + 4SDs, 15.4; Table 1; Fig. 1b) did not detect the anti-P. insidiosum antibodies in any control sera tested (EV range 0.0–9.3). This assay can detect the anti-P. insidiosum antibodies only in the sera from humans (EV range 19.8–72.0) and a dog (at a relatively-low EV, 17.9), but not horses (EV range 6.1–6.6), with pythiosis. The result indicates that the goat anti-human IgG antibody could strongly bind human antibodies and slightly cross-react with dog antibodies. Based on the same serum samples from humans and animals, the anti-human IgG antibody-based ELISA showed equivalent detection specificity (100%), but markedly-lower detection sensitivity (84% vs. 100%), when compared with the protein A/G-based ELISA (Table 1). With a proper cutoff point, all pythiosis sera can ultimately be distinguished from the control sera by the protein A/G-based ELISA (Table 1; Fig. 1a). Unlike the species-specific ELISAs established here (Table 1; Fig. 1b) and by other investigators [10-15], the protein A/G-based ELISA is capable of detecting not only the anti-P. insidiosum antibodies in a single animal species, but also in humans and various animals (i.e., horses and dogs) those are the most affected hosts of pythiosis. A key feature of our ELISA is the use of protein A/G (rather than a species-specific IgG) as a conjugate, which can bind the anti-P. insidiosum immunoglobulins from humans and other animal species. Recently, Intaramat et al. have developed the protein A/G-based ICT, as a rapid and user-friendly assay for diagnosis of pythiosis in humans and animals [16]. They performed a side-by-side performance comparison of their ICT [16] and the species-specific ELISA [11, 13, 15] and showed that ICT has equivalent specificity but relatively-lower sensitivity. One major obstacle for clinical use of ICT is the assay production, which is very complicated and requires a skilled developer and some special reagents that are not available in general clinical laboratories. As opposed to ICT, although ELISA is a multi-step assay and has a longer turnaround time, the production of ELISA is more feasible and requires widely-available reagents. In conclusion, protein A/G-based ELISA has been successfully developed for immunodiagnosis of both human and animal pythiosis. It is a versatile, feasible-to-develop, and functional immunodiagnostic assay.

Limitations

The newly-developed protein A/G-based ELISA overcame the limitation of the previously-established ELISAs [10-15], as it can detect the serum anti-P. insidiosum antibodies in multiple host species, including the most affected hosts: humans, horses, and dogs. Other investigators could adopt our protocol to develop their own in-house ELISA. However, there are several limitations in association with the development and performance evaluation of the assay that need to be addressed: The P. insidiosum strain Pi-S was used to prepare the coating antigen. Although this strain has been studied extensively [21, 22, 27], it is not available in the ATCC and CBS-KNAW culture collection centers. Alternatively, any other P. insidiosum strains could be used to prepare the coating antigen as well. In the evaluation of our protein A/G-based ELISA, only pythiosis serum samples from 4 horses and a dog were tested, due to the low prevalence of the disease in animals in Thailand. The current study focuses on reporting an optimized protocol for the development of protein A/G-based ELISA. Thus, the diagnostic performance (i.e., detection sensitivity and specificity) of the assay was not extensively investigated, using a variety of serum samples from humans and animals with pythiosis and other diseases. Like the previously-established ELISAs, one extra step to perform the assay is to make a serum dilution (our assay requires 1:1600 dilution). This step is necessary for reducing the background ELISA signals from the bindings of non-specific antibodies and P. insidiosum’s crude protein extract. In the future, if a purified P. insidiosum-specific protein is available for coating the ELISA plate, then an undiluted serum could be directly tested. Pythiosis patients usually present with a chronic infection, as the mean duration of symptoms before receiving medical care is several months [3]. Direct detection of P. insidiosum is an indicator of an active infection. Isolation of P. insidiosum from a clinical specimen is difficult and challenging. Antibody detection is an alternative method, providing indirect diagnostic evidence for the P. insidiosum infection. Like the other established immunodiagnostic tests for pythiosis, the protein A/G-based ELISA cannot selectively detect an acute-phase infectious marker, such as IgM. Therefore, it cannot directly differentiate between acute, chronic, and previous P. insidiosum infections. However, in a patient with the typical features of pythiosis, an elevated or high level of the serum anti-P. insidiosum antibodies detected by ELISA suggests an active infection.
  25 in total

1.  Induction of zoospore formation in Thai isolates of Pythium insidiosum.

Authors:  A Chaiprasert; K Samerpitak; W Wanachiwanawin; P Thasnakorn
Journal:  Mycoses       Date:  1990-06       Impact factor: 4.377

2.  Efficiency comparison of three methods for extracting genomic DNA of the pathogenic oomycete Pythium insidiosum.

Authors:  Tassanee Lohnoo; Nujarin Jongruja; Thidarat Rujirawat; Wanta Yingyon; Tassanee Lerksuthirat; Umporn Nampoon; Yothin Kumsang; Pornpit Onpaew; Piriyaporn Chongtrakool; Angsana Keeratijarut; Tristan T Brandhorst; Theerapong Krajaejun
Journal:  J Med Assoc Thai       Date:  2014-03

3.  Detection of the oomycete Pythium insidiosum by real-time PCR targeting the gene coding for exo-1,3-β-glucanase.

Authors:  Angsana Keeratijarut; Tassanee Lohnoo; Wanta Yingyong; Thidarat Rujirawat; Chutatip Srichunrusami; Pornpit Onpeaw; Piriyaporn Chongtrakool; T Tristan Brandhorst; Theerapong Krajaejun
Journal:  J Med Microbiol       Date:  2015-06-30       Impact factor: 2.472

4.  Single nucleotide polymorphism-based multiplex PCR for identification and genotyping of the oomycete Pythium insidiosum from humans, animals and the environment.

Authors:  Thidarat Rujirawat; Thanawat Sridapan; Tassanee Lohnoo; Wanta Yingyong; Yothin Kumsang; Pattarana Sae-Chew; Walaiporn Tonpitak; Theerapong Krajaejun
Journal:  Infect Genet Evol       Date:  2017-08-05       Impact factor: 3.342

5.  Serodiagnosis of human and animal pythiosis using an enzyme-linked immunosorbent assay.

Authors:  L Mendoza; L Kaufman; W Mandy; R Glass
Journal:  Clin Diagn Lab Immunol       Date:  1997-11

Review 6.  Pythium insidiosum: an overview.

Authors:  Wim Gaastra; Len J A Lipman; Arthur W A M De Cock; Tim K Exel; Raymond B G Pegge; Josje Scheurwater; Raquel Vilela; Leonel Mendoza
Journal:  Vet Microbiol       Date:  2010-07-24       Impact factor: 3.293

7.  Development and evaluation of an in-house enzyme-linked immunosorbent assay for early diagnosis and monitoring of human pythiosis.

Authors:  Theerapong Krajaejun; Mongkol Kunakorn; Sopaporn Niemhom; Piriyaporn Chongtrakool; Roongnapa Pracharktam
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

8.  Development of a nested polymerase chain reaction assay for the detection and identification of Pythium insidiosum.

Authors:  Amy M Grooters; Melaney K Gee
Journal:  J Vet Intern Med       Date:  2002 Mar-Apr       Impact factor: 3.333

9.  Hemagglutination test for rapid serodiagnosis of human pythiosis.

Authors:  Thanyasiri Jindayok; Savittree Piromsontikorn; Somboon Srimuang; Kalayanee Khupulsup; Theerapong Krajaejun
Journal:  Clin Vaccine Immunol       Date:  2009-06-03

10.  Biochemical and genetic analyses of the oomycete Pythium insidiosum provide new insights into clinical identification and urease-based evolution of metabolism-related traits.

Authors:  Theerapong Krajaejun; Thidarat Rujirawat; Teerat Kanpanleuk; Pitak Santanirand; Tassanee Lohnoo; Wanta Yingyong; Yothin Kumsang; Pattarana Sae-Chew; Weerayuth Kittichotirat; Preecha Patumcharoenpol
Journal:  PeerJ       Date:  2018-06-05       Impact factor: 2.984

View more
  8 in total

1.  Secretome Profiling by Proteogenomic Analysis Shows Species-Specific, Temperature-Dependent, and Putative Virulence Proteins of Pythium insidiosum.

Authors:  Theerapong Krajaejun; Thidarat Rujirawat; Tassanee Lohnoo; Wanta Yingyong; Pattarana Sae-Chew; Onrapak Reamtong; Weerayuth Kittichotirat; Preecha Patumcharoenpol
Journal:  J Fungi (Basel)       Date:  2022-05-20

2.  Expression, purification, and characterization of the recombinant exo-1,3-β-glucanase (Exo1) of the pathogenic oomycete Pythium insidiosum.

Authors:  Tiwa Rotchanapreeda; Yothin Kumsang; Pattarana Sae-Chew; Thidarat Rujirawat; Tassanee Lohnoo; Wanta Yingyong; Penpan Payattikul; Onrapak Reamtong; Theerapong Krajaejun
Journal:  Heliyon       Date:  2020-06-19

3.  Draft genome sequence of the oomycete Pythium destruens strain ATCC 64221 from a horse with pythiosis in Australia.

Authors:  Theerapong Krajaejun; Weerayuth Kittichotirat; Preecha Patumcharoenpol; Thidarat Rujirawat; Tassanee Lohnoo; Wanta Yingyong
Journal:  BMC Res Notes       Date:  2020-07-09

Review 4.  Review of methods and antimicrobial agents for susceptibility testing against Pythium insidiosum.

Authors:  Hanna Yolanda; Theerapong Krajaejun
Journal:  Heliyon       Date:  2020-04-12

5.  Global Distribution and Clinical Features of Pythiosis in Humans and Animals.

Authors:  Hanna Yolanda; Theerapong Krajaejun
Journal:  J Fungi (Basel)       Date:  2022-02-11

Review 6.  Protein Engineering: Advances in Phage Display for Basic Science and Medical Research.

Authors:  Elena K Davydova
Journal:  Biochemistry (Mosc)       Date:  2022-01       Impact factor: 2.487

7.  Automated Cell-Free Multiprotein Synthesis Facilitates the Identification of a Secretory, Oligopeptide Elicitor-Like, Immunoreactive Protein of the Oomycete Pythium insidiosum.

Authors:  Pattarana Sae-Chew; Thidarat Rujirawat; Yothin Kumsang; Penpan Payattikul; Tassanee Lohnoo; Wanta Yingyong; Chalisa Jaturapaktrarak; Tiwa Rotchanapreeda; Onrapak Reamtong; Tanawut Srisuk; Weerayuth Kittichotirat; Theerapong Krajaejun
Journal:  mSystems       Date:  2020-05-12       Impact factor: 6.496

8.  Sensitive assay design for detection of anti-drug antibodies to biotherapeutics that lack an immunoglobulin Fc domain.

Authors:  Derrick Johnson; Erica Simmons; Sanofar Abdeen; Adam Kinne; Elijah Parmer; Sherri Rinker; Jennifer Thystrup; Swarna Ramaswamy; Ronald R Bowsher
Journal:  Sci Rep       Date:  2021-07-29       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.